EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm

E De Corso, M Caminati, P W Hellings, C Montuori, S Reitsma, V Backer, W J Fokkens

Rhinology Journal · 2025

DOI: 10.4193/rhin25.266 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rhinology Journal, 2025. Verfasst von E De Corso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli Universitary Hospital Foundation, IRCSS, Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophilia, Sinusitis, Nasal Polyps. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab is widely recognised as a highly effective therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP). A rise in blood eosinophil count (BEC) might occur during treatment across all approved indications. In CRSwNP, dupilumab-induced blood eosinophilia (DIBE) is typically of early onset, transient, and asymptomatic without impairing the drug’s efficacy. A review including data from 11 clinical trials on all approved dupilumab indications reported eosinophilia-related clinical manifestations in only 7 of 4,666 patients receiving dupilumab(1). Real-world studies confirm DIBE is largely benign, with only rare AEs requiring dupilumab discontinuation (2,3) such as eosinophilic pneumonia, especially in eosinophilic granulomatosis with polyangiitis (EGPA) patients (2). Such exceedingly rare events were mainly described within the first months of treatment (4), however late onset DIBE (after 6 months) has also been detected, especially in patients dependent on systemic corticosteroids (5).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEosinophiliaSinusitisNasal PolypsRhinitisHumansAlgorithmsChronic Disease

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli Universitary Hospital Foundation, IRCSS, Rome, Italy.
  • Allergy Unit and Asthma Center, Verona Integrated University Hospital and Department of Medicine, University of Verona, Italy.
  • Department of Otorhinolaryngology, Head and Neck Surgery, UZ Leuven, Leuven, Belgium.
  • Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, Rome, Italy.
  • Department of Otorhinolaryngology and Head/Neck surgery, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Otorhinolaryngology, Head and Neck surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

Zitieren

APA

De Corso, E., Caminati, M., Hellings, P. W., Montuori, C., Reitsma, S., Backer, V., & Fokkens, W. J. (2025). Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm. Rhinology Journal. https://doi.org/10.4193/rhin25.266

Vancouver

De Corso E, Caminati M, Hellings PW, Montuori C, Reitsma S, Backer V, et al. Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm. Rhinology Journal. 2025. doi:10.4193/rhin25.266

BibTeX
@article{DeCorso2025,
  author = {De Corso, E and Caminati, M and Hellings, P W and Montuori, C and Reitsma, S and Backer, V and Fokkens, W J},
  title = {Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm},
  journal = {Rhinology Journal},
  year = {2025},
  doi = {10.4193/rhin25.266}
}
Kostenlos starten →